Efficacy and Safety of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Difficult to Treat Migraines: Results from the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Interim Analysis of STS101 Nasal Safety Data From the Phase 3 Open-Label ASCEND Migraine Study

Interim Analysis of Subject Impression Data for STS101 From the Phase 3 Open-Label ASCEND Study 

Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label
ASCEND Study

Subject Impression Data for STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

Nasal Safety Data of STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

STS101 Demonstrates Rapid, Consistent Absorption and Sustained Target Plasma Concentrations of Dihydroergotamine (DHE) With Low Variability 

Relationship of Dihydroergotamine (DHE) Pharmacokinetic Parameters and Clinical Efficacy and Systemic Side Effects 

Long-term safety and tolerability of STS101, a novel investigational dihydroergotamine nasal powder: initial data from the ASCEND study